CTRI/2012/01/002364招募中3 期
Double blind placebo controlled study: To evaluate whether Dexmedetomidine reduces Propofol injection pain.
S N Medical college0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •ASA I and II patients undergoing general anaesthesia
排除标准
- •paediatric patients
- •ASA III and IV patients
- •patients allergic to Dexmedetimidine
- •Neuropsychiatric patients
研究者
相似试验
尚未招募
2 期
Efficacy Evaluation of SARVONUTRA M as Male Wellness AgentCTRI/2022/05/042708SARVOTHAM CARE LIMITED
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-NLTheracos Sub, LLC1,650
已完成
3 期
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse eventsType 2 diabetes and increased risk of cardiovascular adverse events100192801001842410003216NL-OMON47856Theracos Sub, LLC132
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861EUCTR2015-001760-19-DKTheracos Sub, LLC1,650
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-PLTheracos Sub, LLC1,650